While these pathways are compelling targets for treatment given known genetic aberrations in both pathways in pHGG2,5, both compounds are known substrates of ATP-dependent efflux pumps P-gp and BCRP, limiting their brain exposure34,35. Therefore, we selected paxalisib (GDC0084) and mirdametinib...